Iktos
Iktos, a leader in artificial intelligence and robotics, has appointed a new Scientific Advisory Board comprising five 'world-renowned' experts in AI-driven molecular design, lab automation, computational chemistry, first-in-human drug development, and strategic pipeline management.
The expertise of the board will be instrumental in enhancing the AI-first drug discovery platform according to the company, strengthening collaborations, and advancing Iktos’ pipeline towards commercialisation.
At the forefront is Rafael Gomez-Bombarelli, MIT professor and pioneer in generative AI, whose seminal work has been key in the development of AI in Drug Discovery says Iktos.
Thierry Masquelin, the visionary creator of the Lilly Life Science Studio (L2S2) and former automation leader at Recursion Pharmaceuticals, will guide the company in advancing its integrated synthesis, purification, and testing robotic platform. Friedrich Rippmann, former Director of Computational Chemistry and Biologics at Merck KGaA, will contribute his experience in applying computational chemistry methods across the pharmaceutical industry.
Laurent Debussche, former VP Oncology Research at Sanofi, adds decades of experience in advancing first-in-human drug candidates to clinical phases. Rounding out the board, Dominique Bridon, executive chairman at Sybilla Therapeutics, will leverage his leadership in reconciling excellence in science and innovation with entrepreneurial successes, including taking Conjuchem public, to support Iktos in maturing and expanding its AI-first drug candidate pipeline.
